Lunai Bioworks (LNAI) Net Cash Flow (2011 - 2026)
Lunai Bioworks (LNAI) posted quarterly Net Cash Flow of $2.7 million for Q1 2026, up 27.65% year-over-year from $2.1 million in Q1 2025, and up 2285.9% quarter-over-quarter from -$122451.0 in Q4 2025.
Lunai Bioworks (LNAI) Net Cash Flow (2011 - 2026) Analysis & Trends
Lunai Bioworks' Net Cash Flow history runs 16 years deep, the most recent figure standing at $2.7 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 27.65% year-over-year to $2.7 million; the TTM figure through Mar 2026 stood at $2.4 million (up 13.28% YoY), while the FY2025 annual figure was $8125.0, up 100.47% from the prior year.
- Net Cash Flow for Q1 2026 stood at $2.7 million, up from -$122451.0 in the prior quarter.
- The five-year high for Net Cash Flow was $2.7 million in Q1 2026, with the low at -$3.9 million in Q4 2022.
- The 5-year median for Net Cash Flow is -$357092.0 (2023), against an average of -$526446.1.
- Peak annual rise in Net Cash Flow reached 4092.51% in 2025, while the deepest fall reached 153200.46% in 2025.
- Lunai Bioworks' Net Cash Flow stood at -$3.9 million in 2022, then jumped by 90.73% to -$357092.0 in 2023, then jumped by 108.75% to $31255.0 in 2024, then sank by 491.78% to -$122451.0 in 2025, then surged by 2285.9% to $2.7 million in 2026.
- Business Quant data shows LNAI's Net Cash Flow at $2.7 million in Q1 2026, -$122451.0 in Q4 2025, and $538947.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.19 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.58 Bn | 77.59 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.34 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.52 Bn | 51.38 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.04 Bn | 36.94 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.67 Bn | 27.36 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.27 Bn | 26.11 Bn | 358.27 Mn | -37.14 Mn |
| 8 | BioNTech SE | 27.14 Bn | 8.75 Bn | 668.28 Mn | -2.83 Bn |
| 9 | Royalty Pharma | 27.12 Bn | 26.28 Bn | - | 225.59 Mn |
| 10 | Lunai Bioworks | 6.94 Mn | 3.78 Mn | 20,942.00 | 2.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.68 Mn |
| Mar 31, 2026 | 2.68 Mn |
| Dec 31, 2025 | -122,451.00 |
| Dec 31, 2025 | -122,451.00 |
| Sep 30, 2025 | 538,947.00 |
| Sep 30, 2025 | 538,947.00 |
| Jun 30, 2025 | -668,390.00 |
| Jun 30, 2025 | -668,390.00 |
| Mar 31, 2025 | 2.10 Mn |
| Mar 31, 2025 | 2.10 Mn |
| Dec 31, 2024 | 31,255.00 |
| Dec 31, 2024 | 31,255.00 |
| Sep 30, 2024 | 12,855.00 |
| Sep 30, 2024 | 12,855.00 |
| Jun 30, 2024 | -436.00 |
| Jun 30, 2024 | -436.00 |
| Mar 31, 2024 | -84,361.00 |
| Mar 31, 2024 | -84,361.00 |
| Dec 31, 2023 | -357,092.00 |
| Dec 31, 2023 | -357,092.00 |